45 related articles for article (PubMed ID: 23023419)
21. Direct effects of bisphosphonates on breast cancer cells.
Senaratne SG; Colston KW
Breast Cancer Res; 2002; 4(1):18-23. PubMed ID: 11879555
[TBL] [Abstract][Full Text] [Related]
22. Potential anticancer properties of bisphosphonates.
Neville-Webbe HL; Gnant M; Coleman RE
Semin Oncol; 2010 Jun; 37 Suppl 1():S53-65. PubMed ID: 20682373
[TBL] [Abstract][Full Text] [Related]
23. The molecular basis of bisphosphonate activity: a preclinical perspective.
Green J; Clézardin P
Semin Oncol; 2010 Jun; 37 Suppl 1():S3-11. PubMed ID: 20682369
[TBL] [Abstract][Full Text] [Related]
24. Antitumor effects and anticancer applications of bisphosphonates.
Morgan G; Lipton A
Semin Oncol; 2010 Oct; 37 Suppl 2():S30-40. PubMed ID: 21111246
[TBL] [Abstract][Full Text] [Related]
25. Bisphosphonates: preclinical review.
Green JR
Oncologist; 2004; 9 Suppl 4():3-13. PubMed ID: 15459425
[TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo antitumor effects of bisphosphonates.
Clézardin P; Fournier P; Boissier S; Peyruchaud O
Curr Med Chem; 2003 Jan; 10(2):173-80. PubMed ID: 12570716
[TBL] [Abstract][Full Text] [Related]
27. Bisphosphonates in breast cancer: clinical activity and implications of preclinical data.
Aft R
Clin Adv Hematol Oncol; 2011 Mar; 9(3):194-205. PubMed ID: 21475125
[TBL] [Abstract][Full Text] [Related]
28. Antitumor effects of bisphosphonates.
Green JR
Cancer; 2003 Feb; 97(3 Suppl):840-7. PubMed ID: 12548584
[TBL] [Abstract][Full Text] [Related]
29. Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials.
Van Acker HH; Anguille S; Willemen Y; Smits EL; Van Tendeloo VF
Pharmacol Ther; 2016 Feb; 158():24-40. PubMed ID: 26617219
[TBL] [Abstract][Full Text] [Related]
30. The antitumor potential of bisphosphonates.
Clézardin P
Semin Oncol; 2002 Dec; 29(6 Suppl 21):33-42. PubMed ID: 12584693
[TBL] [Abstract][Full Text] [Related]
31. Novel aspects of mevalonate pathway inhibitors as antitumor agents.
Thurnher M; Nussbaumer O; Gruenbacher G
Clin Cancer Res; 2012 Jul; 18(13):3524-31. PubMed ID: 22529099
[TBL] [Abstract][Full Text] [Related]
32. Current trials using bone-targeting agents in prostate cancer.
Tu SM; Lin SH
Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
[TBL] [Abstract][Full Text] [Related]
33. Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.
Saad F; Colombel M
Expert Rev Anticancer Ther; 2010 Dec; 10(12):1991-2002. PubMed ID: 21110764
[TBL] [Abstract][Full Text] [Related]
34. Bisphosphonates in oncology.
Coleman RE; McCloskey EV
Bone; 2011 Jul; 49(1):71-6. PubMed ID: 21320652
[TBL] [Abstract][Full Text] [Related]
35. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates.
Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Fontana D; Angeli A
J Urol; 2001 Dec; 166(6):2023-31. PubMed ID: 11696699
[TBL] [Abstract][Full Text] [Related]
36. The critical role of bisphosphonates to target bone cancer metastasis: an overview.
Singh T; Kaur V; Kumar M; Kaur P; Murthy RS; Rawal RK
J Drug Target; 2015 Jan; 23(1):1-15. PubMed ID: 25203856
[TBL] [Abstract][Full Text] [Related]
37. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates.
Rogers MJ
Calcif Tissue Int; 2004 Dec; 75(6):451-61. PubMed ID: 15332174
[TBL] [Abstract][Full Text] [Related]
38. Bisphosphonates and Cancer: A Relationship Beyond the Antiresorptive Effects.
Teixeira S; Branco L; Fernandes MH; Costa-Rodrigues J
Mini Rev Med Chem; 2019; 19(12):988-998. PubMed ID: 31020940
[TBL] [Abstract][Full Text] [Related]
39. The antineoplastic role of bisphosphonates: from basic research to clinical evidence.
Santini D; Vespasiani Gentilucci U; Vincenzi B; Picardi A; Vasaturo F; La Cesa A; Onori N; Scarpa S; Tonini G
Ann Oncol; 2003 Oct; 14(10):1468-76. PubMed ID: 14504045
[TBL] [Abstract][Full Text] [Related]
40. Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion.
Woodward JK; Coleman RE; Holen I
Anticancer Drugs; 2005 Jan; 16(1):11-9. PubMed ID: 15613899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
